(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Share This 
Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This 
Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Share This 
Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Share This 
Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Share This 
Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Share This Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This 
ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Share This 
Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
Share This 
(Automated Immunoassays)
(MSD-Multiplex ECLIA)
(SPR Biomarker Interactions)
(ImmunoCAP)
(Western Blot Imager)
(Immune Cell Cytokine Release)
(Low Volume Automated ELISA)
(Multiplex Immunoassay)
SAN DIEGO LAB
34,000 Square Feet
CRO
Immunoassay
Mass Spectrometry
USA HQ (DURHAM)
78,685 Square Feet
Discovery
Preclinical/clinal
Manufacturing
BOSTON LAB
26,453 Square Feet
Bioanalytical Services
Diagnostic Testing
EUROPEAN HQ (HAMBURG)
2,777 Square Meters
Assay Development
Validation
Sample Analysis
Global Disease Studies
MELBOURNE LAB
2,777 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
BRISBANE LAB
1,566 Square Meters
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Virology
Immunology
FIH trials & early-phase clinical trials
Central laboratory services
Explore the capabilities of each platform in more detail to learn which option will be best for your unique study. Our team is available for specific guidance on platform selection.
On this episode of Molecular Moments, Dr. Jim McNally chats with DMPK Senior Director Dr. David Johnson, Ph.D., from BioAgilytix
Share This Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This Summary In an article published by Pharmaceutical Technology Europe, BioAgilytix BioAgilytix supplies its assay expertise to describe the appropriate analytical
Share This Summary In an Expert Opinion article published by Contract Pharma, PD Dr. Arno Kromminga of BioAgilytix discusses testing challenges and
Share This Durham, NC, July 21, 2022 – BioAgilytix Labs, LLC (BioAgilytix) has secured a valuable seal of approval for the safety of
Share This Durham, NC, June 30, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical
Share This Cell-based assays are an important tool in drug development. One of the biggest challenges when developing a drug is mimicking the
Share This ADCC Antibody dependent cellular cytotoxicity (ADCC) is a mechanism in host immune defense where antibodies bind to an antigen on
Share This Gene editing isn’t a new concept and has been around for decades. In its infancy, gene editing was time-consuming, inaccurate
Share This
In this Q&A session, Sarah Rieveschl, Business Development Director at BioAgilytix, talks with us about the unique course her career has taken since joining our team six years ago.
Share This 
In this Q&A session, we speak to Beth Heinz, Vice President of Global Business Development at BioAgilytix, as she discusses the evolution of her career with BioAgilytix and the opportunities she sees coming as the industry continues to advance.
Share This 
It is anticipated that biologics will comprise 50% of the top 100 drugs by 2021. But, given the structural complexities of large molecule drugs, adherence to stringent quality standards will be a necessary part of effectively bringing these innovations to market. We discuss why it will be essential for pharma and biotech companies to align with outsourced partners that can deliver the quality science large molecule bioanalysis demands.
Share This 
In this Q&A session, we get to know William Hunter, Director of Business Development and Global Key Accounts at BioAgilytix Europe, as he discusses why he moved to Germany for his role and what he sees coming for BioAgilytix in the industry.
Share This 
In this Q&A session, we get to know Florian Sieglitz, Principal Investigator / Bioanalytical Project Manager (BPM) at BioAgilytix Europe, as he discusses his experiences working in drug development and how his role with BioAgilytix Europe is growing along with the company.
Share This 
In this Q&A session, we get to know Jon Rush, Project Manager at BioAgilytix, as he discusses how he manages collaboration and resource allocation between his teams so that they can work in the most efficient way possible to deliver timely, quality scientific results.
Share This 
Cell-based potency assays, the central tool used to measure drug efficacy during potency testing, allow scientists to see how a particular dose of a drug will react in a given biological system. We discuss how an ideal CRO partner should approach potency assay design and validation under GMP.
Share This 
In this Q&A session, we get to know Daniel Cohen, Business Development Director, Mid-Atlantic and Asia, at BioAgilytix, as he discusses how his work has changed and evolved as the company has grown over the last six years.
Share This 
For bioanalytical CROs, it is of critical importance to build an internal team capable of meeting their pharmaceutical and biotech customers’ drug development goals. However, many overlook the benefits of strategically aligning with external partners – those organizations that can add value to the CRO’s offerings, supplementing their solutions and services to make them more comprehensive and attractive to customers.
Share This 
To gain a better understanding of how BioAgilytix delivers its premium bioanalytical services, it is important to know the people that drive our science. In this Q&A session, we get to know Matt Bray, Scientist/Bioanalytical Project Manager (BPM) at BioAgilytix, and how he has grown with the company since starting as our very first analyst nearly 8 years ago.
Share This 2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 858-652-4699
37 Kent St, Woolloongabba
Queensland, 4102, Australia
2300 Englert Dr
Durham, NC, 27713
919-381-6097
Fax 919-381-6099
9050 Camino Santa Fe
San Diego, CA 92121
858-652-4600
Fax 617-456-0700
37 Kent St,Woolloongabba
Queensland, 4102, Australia
1320 Soldiers Field Road
Boston, MA, 02135
1320 Soldiers Field Road
Boston, MA, 02135
617-456-0700
Fax 617-456-0701
Lademannbogen 10
22339 Hamburg Germany
+49 405267790
85 Commercial Road, Melbourne
Victoria, 3004, Australia
03 9282 2184
Lademannbogen 10
22339 Hamburg Germany
85 Commercial Road, Melbourne
Victoria, 3004, Australia
Copyright © 2022 BioAgilytix Labs.
All rights reserved.
